" class="no-js "lang="en-US"> Immusoft Awarded $8M in Funding from CIRM
Monday, June 17, 2024

Immusoft Awarded $8M in Funding from the California Institute for Regenerative Medicine (CIRM) for MPS I Clinical Program

Immusoft of CA, a wholly owned subsidiary of Immusoft, a clinical-stage cell therapy company dedicated to improving the lives of patients with rare or genetic diseases, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company an $8M funding grant. This funding will support a Phase I study by Immusoft to evaluate the safety and tolerability of ISP-001 (for delivery of alpha-L-iduronidase, or IDUA) in MPS I a rare, childhood genetic disease. The Investigational New Drug Application for the study was cleared by the U.S. Food and Drug Administration as previously announced by Immusoft.

This clinical study is both significant for Immusoft and historic in the field of cell and gene therapies, as ISP-001 will be the first engineered B cell therapy to enter into human clinical trials. Immusoft has pioneered the engineering of B cells to create biofactories for in vivo therapeutic protein delivery, leading the field with over 60 issued and pending patents. The company’s novel B cell platform was designed to circumvent immunogenicity associated with virus-delivered gene therapy and chemotherapy preconditioning associated with stem cell-mediated gene therapy, while enabling durable therapeutic delivery and the possibility to re-dose. This platform has the potential to be used for rare diseases and other conditions modifiable with protein therapeutics.

MPS I affects the body’s ability to produce an essential enzyme, IDUA, resulting in progressive damage to tissues and organs. Children with MPS I require frequent infusions, which impacts their quality of life. The current standard of care for MPS I, depending on severity of disease, is hematopoietic stem cell transplantation (HSCT) or enzyme replacement therapy (ERT), which requires weekly infusions (lasting 3-4 hours) throughout the patient’s lifetime. There is a significant unmet need for new therapies with improved efficacy and convenience. Immusoft’s lead therapeutic, ISP-001, is a novel platform that uses a cell therapy to deliver a gene-encoded medicine. The platform leverages the B cell’s natural ability to produce high levels of antibody proteins. It is the first engineered B cell therapy to enter into human clinical trials. With ISP-001, patient’s B cells are programmed to constantly produce therapeutic proteins, potentially mitigating the need for frequent infusions while potentially improving patient outcomes. This is because ISP-001 cells are expected to release IDUA at therapeutic levels around the clock and on an extended basis – potentially for years.

“We are delighted to partner with CIRM for a second program, this time for MPS I, and appreciate their recognition of the importance of this program. ISP-001 has shown promising results in preclinical studies and we have begun screening patients in our Phase I clinical trial to evaluate its safety and tolerability in treating patients with MPS I. If successful, this novel candidate has the potential to address a significant unmet need in patients who suffer from MPS I and could become a new treatment option to help slow the progression of the disease and improve the quality of life for affected individuals,” said Sean Ainsworth, Immusoft’s Chief Executive Officer.

“Cell-based gene therapy for MPS I such as ISP-001 has the potential to offer long-term disease control and prevent debilitating complications,” said Robert Hayes, Immusoft’s Chief Scientific Officer. “This novel approach also holds the potential to provide patients with durable delivery of the therapeutic 24/7. We are honored that CIRM has recognized the potential of ISP-001 and we look forward to advancing our candidate in MPS I, a rare, genetic childhood disease where patients currently have limited options.”

“Our goal is to always move the most promising research forward as fast as we can,” said Dr. Maria Millan, President and Chief Executive Officer, California Institute for Regenerative Medicine (CIRM). “That’s why these programs are so important. They reflect potential therapeutic approaches that have shown promise in the lab and are ready to take the next step, to undergo further testing and examination to see if they work safely in patients.”

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more